Stockreport

Piper Sandler Reiterates Buy as Seralutinib Momentum Boosts Gossamer (GOSS) Multibagger Case [Yahoo! Finance]

Gossamer Bio, Inc.  (GOSS) 
Last gossamer bio, inc. earnings: 3/24 07:00 am Check Earnings Report
PDF focus lies on its lead asset, Seralutinib, which targets pulmonary arterial hypertension (PAH), a severe condition with limited treatment options. Investor enthusiasm fo [Read more]